Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2001 Dec;92(12):1335–1341. doi: 10.1111/j.1349-7006.2001.tb02158.x

CPT‐11 May Provide Therapeutic Efficacy for Esophageal Squamous Cell Cancer and the Effects Correlate with the Level of DNA Topoisomerase I Protein

Yasuaki Nakajima 1,✉, Satoshi Miyake 2,✉, Kagami Nagai 1,✉, Tatsuyuki Kawano 1,✉, Takehisa Iwai 1,✉
PMCID: PMC5926676  PMID: 11749700

Abstract

CPT‐11 is a potent anti‐cancer drug and a specific inhibitor of DNA topoisomerase I (Topo I). In this study, we aim to evaluate the effects of CPT‐11 on esophageal squamous cell cancers (ESCC) and to determine the correlation between the effects and the levels of Topo I expression. We examined the growth‐inhibitory effect caused by SN‐38, an active metabolite of CPT‐11, in 14 human ESCC cell lines established from 10 primary and 4 metastatic lesions. CPT‐11 was considered effective against 5 cell lines from primary lesions and one from metastatic lesions, and thus may show therapeutic efficacy against both primary and metastatic ESCC tumors. Although Topo I mRNA levels in these 14 ESCC cell lines, as quantitated by northern blot analysis, showed no correlation with the IC50 values, Topo I protein levels, as quantitated by western blot analysis, showed an inverse correlation with the IC50 values. Topo I protein levels could be an indicator of sensitivity to CPT‐11. We also determined Topo I protein levels in 40 ESCC tumors and matched normal mucosae. Thirty‐four tumors showed 1.2‐22.3‐fold increases in Topo I levels. Two patients receiving pre‐operative chemotherapy and one receiving radiotherapy exhibited increased Topo I protein levels in their tumor lesions. It appeared that CPT‐11 could provide selective therapeutic efficacy against ESCC tumors. CPT‐11 may be effective for the treatment of metastatic ESCC tumors and as a second‐line anti‐cancer drug for ESCC.

Keywords: Esophageal squamous cell cancer, CPT‐11, SN‐38, DNA topoisomerase I, Therapeutic efficacy

Full Text

The Full Text of this article is available as a PDF (169.7 KB).

REFERENCES

  • 1. ) Iizuka , T. , Kakegawa , T. , We , H. , Ando , N. , Watanabe , H. , Tanaka , O. , Takagi , I. , Isono , K. , Ishida , K. and Arimori , M.Phase II evaluation of cisplatin and 5‐fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial . Jpn. J. Clin. Oncol. , 22 , 172 – 176 ( 1992. ). [PubMed] [Google Scholar]
  • 2. ) Ilson , D. and Kelsen , D.Systemic therapy in esophageal cancer . In “ Comprehensive Textbook of Thoracic Oncology ,“ ed. Aisner J. , Arriagada R. and Green M. , pp. 630 – 649 ( 1996. ). William & Wilkins; , Baltimore . [Google Scholar]
  • 3. ) Wall , M. E. , Wani , M. C. , Cook , C. E. , Palmar , K. H. , MacPhail , A. T. and Sim , G. A.Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata . J. Am. Chem. Soc. , 88 , 3888 – 3890 ( 1966. ). [Google Scholar]
  • 4. ) Gallo , R. C. , Whang‐Peng , J. and Adamson , R. H.Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin . J. Natl. Cancer Inst. , 46 , 789 – 795 ( 1971. ). [PubMed] [Google Scholar]
  • 5. ) Gottlieb , J. A. , Guarino , A. M. , Call , J. B. , Oliverio , V. T. and Block , J. B.Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC‐100880) . Cancer Chemother. Rep. , 54 , 461 ( 1970. ). [PubMed] [Google Scholar]
  • 6. ) Muggia , F. M. , Creaven , P. J. , Hansen , H. H. , Cohen , M. H. and Sealwry , O. S.Phase I clinical trial of weekly and daily treatment with camptothecin (NSC‐100880) . Cancer Chemother. Rep. , 56 , 515 ( 1972. ). [PubMed] [Google Scholar]
  • 7. ) Schaeppi , U. , Fleischman , R. W. and Cooney , D. A.Toxicity of camptothecin (NSC‐100880) . Cancer Chemother. Rep. [3] , 5 , 25 – 36 ( 1974. ). [PubMed] [Google Scholar]
  • 8. ) Kunimoto , T. , Nitta , K. , Tanaka , T. , Uehara , N. , Baba , H. , Takeuchi , M. , Yokokura , T. , Sawada , S. , Miyasaka , T. and Mutai , M.Antitumor activity of 7‐ethyl‐10‐[4‐(l‐piperi‐dino)‐l‐piperidino]carbonyloxycamptothecin, a novel water‐soluble derivative of camptothecin, against murine tumors . Cancer Res. , 47 , 5944 – 5947 ( 1987. ). [PubMed] [Google Scholar]
  • 9. ) Kaneda , K. , Nagata , T. , Furuta , T. and Yokokura , T.Metabolism and pharmacokinetics of the camptothecin analogue CPT‐11 in the mouse . Cancer Res. , 50 , 1715 – 1720 ( 1990. ). [PubMed] [Google Scholar]
  • 10. ) Kawato , Y. , Aonuma , M. , Hirota , Y. , Kuga , H. and Sato , K.Intracellular roles of SN‐38, a metabolite of the camptothe‐cin derivative CPT‐11, in the antitumor effect of CPT‐11 . Cancer Res. , 51 , 4187 – 4191 ( 1991. ). [PubMed] [Google Scholar]
  • 11. ) Tsuji , K. , Kaneda , N. , Kado , K. , Yokokura , T. , Yoshimoto , T. and Tsuru , D.CPT‐11 converting enzyme from rat serum: purification and some properties . J. Pharmacobiodyn. , 14 , 341 – 349 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Tanizawa , A. , Fujimori , A. , Fujimori , Y. and Pommier , Y.Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials . J. Natl. Cancer Inst. , 86 , 836 – 842 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Hsiang , Y. H. , Lihou , M. G. and Liu , L. F.Arrest of replication forks by drug‐stabilized topoisomerase I‐DNA cleav‐able complexes as a mechanism of cell killing by camptothecin . Cancer Res. , 49 , 5077 – 5082 ( 1989. ). [PubMed] [Google Scholar]
  • 14. ) Holm , C. , Covey , J. M. , Kerrigan , D. and Pommier , Y.Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells . Cancer Res. , 49 , 6365 – 6368 ( 1989. ). [PubMed] [Google Scholar]
  • 15. ) Sugimoto , Y. , Tsukahara , S. , Oh‐hara , T. , Isoe , T. and Tsuruo , T.Decreased expression of DNA topoisomerase I in camptothecin‐resistant tumor cell lines as determined by a monoclonal antibody . Cancer Res. , 50 , 6925 – 6930 ( 1990. ). [PubMed] [Google Scholar]
  • 16. ) Jansen , W. J. M. , Zwart , B. , Hulscher , S. T. M. , Giaccone , G. , Pinedo , H. M. and Boven , E.CPT‐11 in human colon‐cancer cell lines and xenografts: characterization of cellular sensitivity determinants . Int. J. Cancer , 70 , 335 – 340 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Giovanella , B. C. , Stehlin , J. S. , Wall , M. E. , Wani , M. C. , Nicholas , A. W. , Liu , L. F. , Silber , R. and Potmesil , M.DNA topoisomerase I‐targeted chemotherapy of human colon cancer in xenografts . Science , 246 , 1046 – 1048 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Husain , L , Mohler , J. L. , Seigler , H. F. and Besterman , J. M.Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor‐type specificity and implications for cancer chemotherapy . Cancer Res. , 54 , 539 – 546 ( 1994. ). [PubMed] [Google Scholar]
  • 19. ) Ohashi , N. , Fujiwara , Y. , Yamaoka , N. , Katoh , O. , Satow , Y. and Yamakido , M.No alteration in DNA topoisomerase I gene related to CPT‐11 resistance in human lung cancer . Jpn. J. Cancer Res. , 87 , 1280 – 1287 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. ) van Ark‐Otte , J. , Kedde , M. A. , van der Vijgh , W. J. , Dingemans , A. M. , Jansen , W. J. , Pinedo , H. M. , Boven , E. and Giaccone , G.Determinants of CPT‐11 and SN‐38 activities in human lung cancer cells . Br. J. Cancer , 77 , 2171 – 2176 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. ) Nishihira , T. , Hashimoto , Y. , Katayama , M. , Mori , S. and Kuroki , T.Molecular and cellular features of esophageal cancer cells . J. Cancer Res. Clin. Oncol. , 119 , 441 – 449 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) Carmichael , J. , DeGraff , W. G. , Gazdar , A. F. , Minna , J. D. and Mitchell , J. B.Evaluation of a tetrazolium‐based semi‐automated colorimetric assay: assessment of chemosensitivity testing . Cancer Res. , 47 , 936 – 942 ( 1987. ). [PubMed] [Google Scholar]
  • 23. ) Sambrook , J. , Fritsch , E. F. and Maniatis , T. “ Molecular Cloning: A Laboratory Manual “ ( 1989. ). Cold Spring Harbor Laboratory; , Cold Spring Harbor, New York . [Google Scholar]
  • 24. ) Harlow , E. and Lane , D. “ Anitbodies: A Laboratory Manual “ ( 1988. ). Cold Spring Harbor Laboratory; , Cold Spring Harbor, New York . [Google Scholar]
  • 25. ) Taguchi , T. , Wakui , A. , Hasegawa , K. , Niitani , H. , Furue , H. , Ohta , K. and Hattori , T.Phase I clinical study of CPT‐11 . Jpn. J. Cancer Chemother. , 17 , 115 – 120 ( 1990. ). [PubMed] [Google Scholar]
  • 26. ) Ilson , D. H. , Saltz , L. , Enzinger , P. , Huang , Y. , Kornblith , A. , O'Reilly , E. , Schwartz , G. , DeGroff , J. , Gonzalez , G. and Kelsen , D. P.Phase U trial of weekly irinotecan plus cisplatin in advanced esophageal cancer . J. Clin. Oncol. , 17 , 3270 – 3275 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 27. ) Aiba , K. , Funakoshi , T. , Mizunuma , N. , Dobashi , N. , Hirano , A. , Sano , M. , Kuraishi , Y. , Kamada , M. , Ohno , N. , Sugimoto , Y. , Tsuruo , T. , Shibata , H. and Horikoshi , N.Antitumor effect of SN‐38, active form of CPT‐11, on human colorectal cancer cell line . Jpn. J. Cancer Chemother. , 21 , 1601 – 1606 ( 1994. ). [PubMed] [Google Scholar]
  • 28. ) Davis , S. , Shanmugathasa , M. and Kessler , W.cis‐Dichlorodiammineplatinum(II) in the treatment of esophageal carcinoma . Cancer Treat. Rep. , 64 , 709 – 711 ( 1980. ). [PubMed] [Google Scholar]
  • 29. ) Panettiere , F. J. , Leichman , L. , O'Bryan , R. , Haas , C. and Fletcher , W.cis‐Diamminedichloride platinum(U), an effective agent in the treatment of epidermoid carcinoma of the esophagus; a preliminary report of an ongoing Southwest Oncology Group study . Cancer Clin. Trials , 4 , 29 – 31 ( 1981. ). [PubMed] [Google Scholar]
  • 30. ) Engstrom , P. F. , Lavin , P. T. and Klaassen , D. J.Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma . Cancer Treat. Rep. , 67 , 713 – 715 ( 1983. ). [PubMed] [Google Scholar]
  • 31. ) Horwitz , S. B. and Horwitz , M. S.Effects of camptothecin on the breakage and repair of DNA during the cell cycle . Cancer Res. , 33 , 2834 – 2836 ( 1973. ). [PubMed] [Google Scholar]
  • 32. ) Tanizawa , A. , Kohn , K. W. , Kohlhagen , G. , Leteurtre , F. and Pommier , Y.Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives . Biochemistry , 34 , 7200 – 7206 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 33. ) Pommier , Y.Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins . Semin. Oncol. , 23 , 3 – 10 ( 1996. ). [PubMed] [Google Scholar]
  • 34. ) Romig , H. and Richter , A.Expression of the topoisomerase I gene in serum stimulated human fibroblasts . Biochim. Biophys. Acta , 1048 , 274 – 280 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 35. ) Romig , H. and Richter , A.Expression of the type I DNA topoisomerase gene in adenovirus‐5 infected human cells . Nucleic Acids Res. , 18 , 801 – 808 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES